Biochemical and Biophysical Research Communications
An oncolytic adenovirus enhances antiangiogenic and antitumoral effects of a replication-deficient adenovirus encoding endostatin by rescuing its selective replication in nasopharyngeal carcinoma cells
Introduction
Oncolytic adenovirus (Ad) has been demonstrated to lyse selectively cancer cells but not normal cells [1]. E1B55k-deleted Ad dl1520 [2] and H101 [3] are the oncolytic Ad with the most extensive investigation, were firstly applied in clinical trials and H101 has been approved for the clinical application to treat squamous cell carcinoma of the head and neck in China.
The antiangiogenic therapy is another attractive strategy for cancer treatment. Endostatin was previously considered the most potent endogenous angiogenesis inhibitor [4] and was rapidly moved to clinical trials. However, the high instability and shorter half-life made it difficult for clinical application [5]. Promisingly, the antiangiogenic gene therapy can overcome these problems and is likely a potential new approach for the treatment of cancer.
An Ad vector encoding a secreted human endostatin (Ad-Endo) has been confirmed to inhibit tumor growth through antiangiogenesis [6]. The results of preclinical, phase I/II clinical trials suggested that the treatment of solid tumor with Ad-Endo is likely a safe and promising approach [7], [8] (ClinicalTrials.gov identifier, NCT00634595). Even so, it is necessary to find a way for overcoming the problem of limited curative effect due to limited endostatin expression [7], [9], [10].
We presumed that the selective replication of oncolytic Ad would rescue Ad-Endo genome amplification and promote endostatin expression. In this study, we investigated the antitumor effects of the combined treatment of Ad-Endo and H101 on Nasopharyngeal carcinoma (NPC). The results indicate that Ad-Endo and H101 have a synergistic antitumor effect on NPC, which resulted from the promoted antiangiogenic effect of Ad-Endo by H101 and the enhanced oncolysis of H101 by Ad-Endo.
Section snippets
Cells and plasmids
Human NPC CNE-1, CNE-2 cells contain a mutant p53 at codon 280, whereas C666-1 harbors a deletion at codon 249 of p53 and Epstein-Barr virus (EBV) DNA. Human umbilical vein endothelial cells (HUVEC) were cultured in Ham’s F12 nutrient mixture supplemented with endothelial cell growth supplement (BD Biosciences) and 10% FBS. human embryonic kidney 293 cells and CNE-1, CNE-2 cells were cultured in DMEM containing 10% FBS (Invitrogen), and C666-1 cells were cultured in RPMI 1640 with 15% FBS. The
Results and discussion
Ad-Endo has been showed that can inhibit tumor growth through antiangiogenic effects in our previous study [6]. E1B55kD-deficient Ad, such as H101 or Onyx-015, has been confirmed that can selectively lyse cancer cells with abnormal p53 pathway [1], [13]. In addition, late viral RNA export, the cell cycle status of host cells, viral infectivity, and the expression of heat shock proteins may also determine the tumor selectivity of E1B55kD-deficient Ad [13], [14]. In previous studies,
Acknowledgments
This study was supported by National Natural Science Foundation of China (Nos. 81272638, 31170151), National Key Basic Research Program of China (No. 2012CB519003), National High Technology Research and Development Program of China (Nos. 2012AA020803, 2012AA02A204) and Guangzhou Key Program of Science and Technology (No. 2012Y2-00026).
References (21)
- et al.
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
Cancer Cell
(2004) - et al.
Bioactivity and stability analysis of endostatin purified from fermentation supernatant of 293 cells transfected with Ad/rhEndo
Protein Expr. Purif.
(2007) Targeting gene-virotherapy of cancer and its prosperity
Cell Res.
(2006)- et al.
ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents
Nat. Med.
(1997) China approves world’s first oncolytic virus therapy for cancer treatment
J. Natl. Cancer Inst.
(2006)- et al.
Antiangiogenic therapy: a novel approach to overcome tumor hypoxia
Chin. J. Cancer
(2010) Endostatin derivative angiogenesis inhibitors
Chin. Med. J. (Engl)
(2009)- et al.
Adenovirus-mediated intra-tumoral delivery of the human endostatin gene inhibits tumor growth in nasopharyngeal carcinoma
Int. J. Cancer
(2006) - et al.
A phase I clinical trial of an adenovirus-mediated endostatin gene (E10A) in patients with solid tumors
Cancer Biol. Ther.
(2007) - et al.
Long-term toxicity studies in Canine of E10A, an adenoviral vector for human endostatin gene
Hum. Gene Ther.
(2007)
Cited by (12)
The use of geroprotectors to prevent multimorbidity: Opportunities and challenges
2021, Mechanisms of Ageing and DevelopmentCitation Excerpt :However, when rapamycin was given at a later stage of disease in the same mice (15−18 months of age), no reversal was observed (Majumder et al., 2011). In another model of Alzheimer’s disease, administration of rapamycin restored vascular and metabolic functions in the young mice expressing human APOE4 gene, the major genetic risk factor for the condition (Lin et al., 2017; Liu et al., 2013). As cerebrovascular impairments are proposed to be initiating events in the development of Alzheimer’s, this study reinforces the notion that rapamycin may be able to reverse very early signs of disease (Jahrling et al., 2018; Lin et al., 2017, 2013; Van Skike et al., 2018).
Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
2023, International Journal of OncologySIRT2 plays complex roles in neuroinflammation neuroimmunology-associated disorders
2023, Frontiers in ImmunologyResearch Progress on Gene Therapy of Endostatin Based on Different Viral Vectors
2021, Chinese Pharmaceutical JournalThe Role of HDAC6 in Autophagy and NLRP3 Inflammasome
2021, Frontiers in ImmunologyOverexpression of lncrna snhg1 were suitable for oncolytic adenoviruse h101 therapy in oral squamous-cell carcinoma
2020, OncoTargets and Therapy
- 1
These authors contributed equally in this paper.